Autopsy report · NCT01420965

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

“Drug supply issues”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 4 years 3 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Augusta University

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms

Interventions

CT-011 (Anti-PD1 Antibody); Sipuleucel-T (Provenge); Cyclophosphamide

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
  “Problem with drug supply” (92% match in meaning)
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
  “Insufficient drug supply” (84% match in meaning)
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
  “Study drug supply issue” (83% match in meaning)
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  “Lack of drug supply” (83% match in meaning)
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
  “Drug supply” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.